NCT00024557View on ClinicalTrials.gov

Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 30, 2001

Primary Completion Date

June 30, 2006

Study Completion Date

July 31, 2007

Conditions
Malignant GliomaGlioblastoma MultiformeAnaplastic AstrocytomaMixed OligoastrocytomaMalignant Astrocytoma
Interventions
DRUG

IL13-PE38QQR

PROCEDURE

targeted fusion protein therapy

PROCEDURE

surgery

Trial Locations (4)

10021

Memorial Sloan-Kettering Cancer Center, New York

77030

MD Anderson Cancer Center, Houston

94143

University of California San Francisco, San Francisco

06520

Yale University, New Haven

Sponsors
All Listed Sponsors
lead

INSYS Therapeutics Inc

INDUSTRY

NCT00024557 - Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients | Biotech Hunter | Biotech Hunter